Trial reportFrontiers in immunology2026
Anlotinib combined with chemoradiotherapy for postoperative isolated lymph node recurrence of ESCC: a phase II study.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative lymph node recurrence in esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis and lacks standardized treatment. Radioresistance and aberrant immune/inflammatory tumor microenvironment (TME) are major barriers limiting the efficacy of concurrent chemoradiotherapy (CRT). This study aimed to evaluate the efficacy, safety, and immune-related radiosensitising mechanisms of anlotinib combined with CRT for postoperative isolated lymph node recurrence of ESCC. Methods: In this single-arm phase II trial, 47 patients with postoperative isolated lymph node recurrence of ESCC received anlotinib plus concurrent CRT. Tumor response and safety were assessed per RECIST version 1.1 and NCI-CTCAE version 4.0. Peripheral blood immune indicators (CD4 Results: The median progression-free survival (PFS) and overall survival (OS) were 20.2 and 30.7 months, respectively. The objective response rate (ORR) was 91.5% (12.8% complete response, 78.7% partial response), with a 100% disease control rate (DCR). The mean lymph node diameter reduction was 60.1 ± 18.0%. Treatment was well tolerated; Grade ≥ 3 treatment-related adverse events occurred in 42.6% of patients and were reversible without treatment interruption. Peripheral blood immune monitoring showed a significant increase in the CD4 Conclusions: Anlotinib combined with CRT achieves favorable efficacy and manageable toxicity in postoperative nodal recurrent ESCC. This regimen significantly reshapes the peripheral immune profile and overcomes radioresistance via dual modulation of tumor vasculature and immune-inflammatory pathways. It represents a promising salvage strategy worthy of validation in multicenter randomized controlled trials. Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR1900023677.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.